Vascular Endothelial Growth Factor Inhibitors and the Risk of Aortic Aneurysm and Aortic Dissection

• DOI: 10.1001/jamanetworkopen.2024.0940
• Publication Date: 2024-03-04T16:01:13Z
• Authors: Chia-Wei Wu; Hsin-Yi Huang; Shin-Yi Lin; Chi-Chuan Wang; Chih-Fen Huang; I-Hui Wu
• Keywords: Male; Vascular Endothelial Growth Factor A; Sulfonamides; Indazoles; Sorafenib; Aortic Aneurysm; Pancreatic Neoplasms; Aortic Dissection; 03 medical and health sciences; Pyrimidines; 0302 clinical medicine; Case-Control Studies; Sunitinib; Humans; Original Investigation; Aged

ImportanceVascular endothelial growth factor pathway inhibitors (VPIs) pose a concern for aortic aneurysm (AA) and aortic dissection (AD), signaling potential vascular disease development.ObjectiveTo investigate VPI-associated AA and AD.Design, Setting, and ParticipantsThis case-control study with a nested design used full population data from a national claims database in Taiwan between 2011 and 2019. Eligible participants were aged 20 years or older with kidney, hepatic, gastrointestinal, or pancreatic cancer diagnosed between January 1, 2012, and December 31, 2019. The first cancer diagnosis date was defined as the cohort entry date. Cases were patients who received a diagnosis of AA or AD in hospitalizations or emergency visits between the cohort entry date and December 31, 2019. Controls were matched by ratio (up to 1:5) based on age, sex, cancer type, cohort entry date, and the index date (ie, the first AA or AD event date). Data analysis was performed between January 2022 and December 2023.ExposuresUse of the oral VPIs sorafenib, sunitinib, and pazopanib between cohort entry date and index date.Main Outcomes and MeasuresIn the primary analysis, AA and AD were evaluated compositely, while in the secondary analyses, they were evaluated separately. Adjusted odds ratios (aORs) were calculated using conditional logistic regression to assess the association with VPI use (sorafenib, sunitinib, and pazopanib) considering various VPI exposure windows and cumulative use.ResultsA total of 1461 cases were included (mean [SD] age, 73.0 [12.3] years; 1118 male patients [76.5%]), matched to 7198 controls. AA or AD risk increased with a VPI exposure of 100 days or less before the index date (aOR, 2.10; 95% CI, 1.40-3.15), mainly from VPI-associated AD (aOR, 3.09; 95% CI, 1.77-5.39). Longer VPI duration (68 days or more: aOR, 2.64; 95% CI, 1.66-4.19) and higher cumulative dose (61 or more defined daily doses: aOR, 2.65; 95% CI, 1.66-4.23) increased the risk.Conclusions and RelevanceThe use of the 3 study VPIs (sorafenib, sunitinib, and pazopanib) was associated with an increased risk of AA and AD in patients with cancer, essentially all of the risk from VPI-associated AD. Future studies are needed to determine the risk factors of VPI-associated AA and AD, as well as to establish a class effect.